How much cash does Citius Oncology, Inc. generate?

Citius Oncology, Inc. (CTOR) generated -$13.9M in operating cash flow over the trailing twelve months.

Where does Citius Oncology, Inc.'s cash flow data come from?

Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Citius Oncology, Inc. CTOR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25
Net income	-$42.51M-63.6%	-$23.64M-2.4%	-$24.76M-17.1%	-$26.58M-87.5%	-$25.98M-196%
Stock-based compensation	$11.91M+58.3%	$10.47M+41.6%	$8.32M+11.0%	$7.69M+21.6%	$7.52M+54.9%
Deferred income taxes	——	$1.06M+51.8%	$1.06M+83.5%	$936.72K+62.6%	$816.48K+41.8%
Change in accounts receivable	——	——	——	——	——
Change in inventories	$5.95M-26.9%	$6.89M-10.7%	$12.65M+493%	$9.47M—	$8.14M—
Change in accounts payable	$1.21M-83.2%	$4.57M-19.4%	$9.52M+293%	$8.67M+976%	$7.17M+3,940%
Change in accrued liabilities	——	——	——	——	$8.72M+70,211%
Change in prepaid expenses	——	——	——	——	——
Net cash from operating activities	-$13.93M-586%	-$11.47M-1,252%	-$5.49M-1,088%	-$3.43M-1,319%	-$2.03M—
Purchases of intangible assets	$7.88M+46.5%	$8.71M+68.0%	$5.75M+15.0%	$5.56M—	$5.38M—
Acquired in-process research and development	——	$44.81M—	$6.42M—	$38.21M—	——
Net cash from investing activities	-$7.88M+76.8%	-$8.71M-12.3%	-$5.75M+24.0%	-$34.12M-731%	-$33.93M-234%
Proceeds from issuance of debt	——	——	——	——	——
Repayments of debt	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	——	$26.5M+175%	$15.17M+115%	$40.53M+287%	$37.96M—
Net increase (decrease) in cash	$670.12K—	$6.31M—	$3.92M—	$2.72M—	——
Interest paid	——	$155K—	$187.39K—	——	——
Amortization Of Inprocess Research And Development	——	——	——	——	——
Accounts payable	$1.21M-83.2%	$4.57M-19.4%	$9.52M+293%	$8.67M+976%	$7.17M+3,940%
Increase Decrease In Due To Related Parties	$3.28M-70.2%	$8.6M—	$8.92M—	$9.7M—	$11.01M—
Increase (Decrease) in Prepaid Expense	——	——	——	——	——
Merger-related charges and other	——	——	——	——	——
Payments to Acquire in Process Research and Development	——	——	——	——	——
Payments to Acquire Intangible Assets	$7.88M+46.5%	$8.71M+68.0%	$5.75M+15.0%	$5.56M—	$5.38M—
Repayments Of Notes Payable	——	——	——	——	——
Adjustments To Additional Paid In Capital Other	——	——	——	——	——
Cost Of Revenue	——	——	——	——	——
Earnings per common share - diluted (in dollars per share)	-$0.47-27.0%	-$0.31+6.1%	-$0.34-9.7%	-$0.38-47.6%	-$0.37-57.4%
Effective Income Tax Rate Reconciliation Permanent Differences	——	——	——	——	——
Gain On Sale Of New Jersey Net Operating Losses	——	——	——	——	——
General and administrative costs	$29.7M+175%	$8.32M-16.4%	$8.78M+7.8%	$11.15M+88.3%	$10.81M+84.4%
Gross Profit	——	——	——	——	——
Income before provision for income taxes	-$41.95M-66.7%	-$22.58M-0.9%	-$23.7M-15.2%	-$25.64M-51.4%	-$25.16M-64.1%
Interest expense	——	——	$218.03K—	——	——
Interest Expense, Nonoperating	$296.9K—	——	——	——	——
Investment Income Interest	$90.2K—	$55.57K—	$36.37K—	——	——
Other Income - Net	$1.66M—	-$153.8K—	-$181.66K—	——	——
Other Expenses	$111.76K-8.1%	$114.19K-4.2%	$116.61K-2.1%	$119.14K+0.1%	$121.57K+2.1%
Other Research And Development Expense	$1.91M-2.5%	$1.92M-2.1%	$1.92M-2.2%	$1.92M+3.5%	$1.96M+14.2%
Payments Of Merger Related Costs Financing Activities	——	——	——	——	——
Revenues	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Capital Contribution Of Due To Related Party By Parent	——	——	——	——	——
IP Ramp D Milestones Included In License Payable	——	——	——	——	——
Prepaid Manufacturing Transferred To Inventory	——	——	$1.37M-77.7%	$2.56M—	$3.75M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Citius Oncology, Inc. generate?: Citius Oncology, Inc. (CTOR) generated -$13.9M in operating cash flow over the trailing twelve months.
Where does Citius Oncology, Inc.'s cash flow data come from?: Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.